EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
Authors:
- for the EARLY Registry GroupFGfor the EARLY Registry Group
- Anselm K GittAGAnselm K Gitt
- Peter BaumgartPBPeter Baumgart
- Peter BramlagePBPeter Bramlage
- Felix MahfoudFMFelix Mahfoud
- Sebastian A PotthoffSPSebastian A Potthoff
- Jochen SengesJSJochen Senges
- Steffen SchneiderSSSteffen Schneider
- Hartmut BuhckHBHartmut Buhck
- Roland E SchmiederRSRoland E Schmieder
Open Access
- 2 July 2013
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 13 (1) , 1-8
Abstract
Arterial hypertension is highly prevalent but poorly controlled. Blood pressure (BP) reduction substantially reduces cardiovascular morbidity and mortality. Recent randomized, double-blind clinical trials demonstrated that azilsartan medoxomil (AZM) is more effective in reducing BP than the ubiquitary ACE inhibitor ramipril. Therefore, we aimed to test whether these can be verified under clinical practice conditions. The “Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy” (EARLY) registry is a prospective, observational, national, multicenter registry with a follow-up of up to 12 months. It will include up to 5000 patients on AZM or ACE-inhibitor monotherapy in a ratio of 7 to 3. A subgroup of patients will undergo 24-hour BP monitoring. EARLY has two co-primary objectives: 1) Description of the safety profile of azilsartan and 2) achievement of BP targets based on recent national and international guidelines for patients treated with azilsartan in comparison to those treated with ACE-inhibitors. The most important secondary endpoints are the determination of persistence with treatment and the documentation of cardiovascular and renal events. Recruitment commenced in January 2012 and will be completed by February 2013. The data obtained will supplement previous results from randomized controlled trials to document the potential value of utilizing azilsartan medoxomil in comparison to ACE-inhibitor treatment for target BP achievement in clinical practice.Keywords
This publication has 19 references indexed in Scilit:
- Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramiprilJournal of Human Hypertension, 2013
- Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical studyHypertension Research, 2012
- Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU SoonVascular Health and Risk Management, 2011
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure MonitoringThe Journal of Clinical Hypertension, 2011
- Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 HypertensionHypertension, 2011
- In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function StudiesThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood PressureThe Journal of Clinical Hypertension, 2011
- Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practiceVascular Health and Risk Management, 2010
- External Validity of Clinical Trials in Acute Myocardial InfarctionArchives of internal medicine (1960), 2007
- Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole BioisosteresJournal of Medicinal Chemistry, 1996